Profile Image

Conjoint Professor Stephen Ackland

Director, Hunter Cancer Research Alliance

Office of the PVC Health and Medicine (Pharmacy and Experimental Pharmacology)

Career Summary

Biography

Prof. Stephen Ackland is Staff Specialist, Department of Medical Oncology, Calvary Mater Newcastle Hospital and Professor, Faculty of Health, University of Newcastle. He is the Director, Hunter Cancer Research Alliance; Director, University of Newcastle Priority Research Centre for Cancer Research Innovation and Translation; Director of Clinical Cancer Research Network HNE Health; Co-director of Hunter Medical Research Institute Cancer Research Program. He has played a key role in organisation, harmonisation and enhancements of translational and clinical research locally, on a state basis and nationally. He is Editor-in-Chief, Asia-Pacific Journal of Clinical Oncology. He is an inaugural member of the PRIMe consortium (Pharmacogenomics Research towards Individualised Medicine), a NSW Cancer Council-funded collaboration of 8 NSW hospitals and research institutes with the aim of facilitating cancer pharmacogenomics research in NSW.

Committee appointments include: Honorary Secretary, Medical Oncology Group of Australia, 1997-2000; Chairman, Medical Oncology Group of Australia, 1999-2000. Chair, Specialist Advisory Committee in Medical Oncology, RACP, 1999-2000; AMWAC Committee on Medical Oncology 1999-2001; President, Clinical Oncological Society of Australia 2004-2005; Director, Australian & New Zealand Breast Cancer Trials Group, 2007-, (and Chairman 2015-2017); Director, NSW Cancer Council, 2006-2014.

He is the author of over 90 original publications in peer-reviewed journals and first author on 18 of these. He was co-owner of 2 patents. He has been investigator on 25 grants totaling $10.9m, including lead investigator on 8 grants valued at approx $4m. He has had extensive involvement in cancer clinical trials, clinical pharmacokinetics and pre-clinical pharmacology of anticancer drugs and combinations. He has been the principal investigator on two Australian multi-institutional randomised controlled trials run through cancer cooperative trials groups, and principal investigator on a number of phase I & II trials. He is/has been a member of the trial management committee of a number of cancer cooperative trials groups, undertaking multi-institutional trials in breast and GI cancer.

Research Expertise
Basic and clinical pharmacology of anticancer drugs, including drug measurement, pharmacokinetics pharmacodynamics, and relevant genetics/genomics. Clinical trials in cancer mainly medical oncology.

Teaching Expertise
Teaches medical nursing and allied health students and postgraduates in basic and clinical oncology. Also science students in pharmacology

Administrative Expertise
Director of Medical Oncology 2001-2005. Manages the Medical Oncology research program (9 staff, clinical and lab).Chair of HMRI Cancer Research Program 2003 -present. President of Clinical Oncological Soc of Australia 2004 and 2005. Chairman, Medical Oncology Group of Australia 1999 and 2000. Board member, TheraPPy Pty Ltd 2004-2006. Board member Cancer Council NSW 2006-2009. Member, International Affairs Committee, Am Soc of Clin Oncol, 1998-2000 and 2006-2009 


Qualifications

  • Bachelor of Medicine & Surgery, University of Melbourne

Keywords

  • Clinical Trials
  • Medical Oncology
  • Medicine
  • Pharmacogenomics
  • Pharmacokinetics
  • Pharmacology

Fields of Research

Code Description Percentage
110399 Clinical Sciences not elsewhere classified 35
111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified 35
111299 Oncology and Carcinogenesis not elsewhere classified 30

Professional Experience

UON Appointment

Title Organisation / Department
Director, Hunter Cancer Research Al University of Newcastle
Office of the PVC Health and Medicine
Australia

Academic appointment

Dates Title Organisation / Department
1/07/2007 -  Director ANZ Breast Cancer Trials Group
Australia
1/09/2006 - 31/12/2014 Director Cancer Council NSW
1/01/2005 -  Editor-in-Chief, Editorial Board - Asia Pacific Journal of Clinical Oncology

Overall responsibility for the strategy, operation and reputation of the Journal (30+ Associate Editors, 40 Editorial Board members)

Asia Pacific Journal of Clinical Oncology
Japan
1/01/2004 - 1/01/2006 President Clinical Oncological Society of Australia
1/06/1984 - 1/06/1987 Fellow in Haematology and Oncology University of Chicago
Haematology and Medical Oncology
United States

Membership

Dates Title Organisation / Department
1/09/2006 - 1/09/2009 Member, International Affairs Committee, ASCO

The IAC advises the Board on strategies and procedures to support and engage the increasing international membership (about 15,000) of the Society

American Society of Clinical Oncology (ASCO)
United States
1/01/2006 - 1/12/2008 Membership - ASCO International Affairs Committee ASCO International Affairs Committee
Australia
1/01/1999 - 1/01/2001 Chairman Medical Oncology Group of Australia
Australia
1/01/1997 - 1/12/1999 Membership - ASCO International Affairs Committee ASCO International Affairs Committee
Australia
1/01/1994 -  Membership -Scientific Advisory Committee Australasian GI Trials Group
Australia

Professional appointment

Dates Title Organisation / Department
15/07/2015 -  Chairman ANZ Breast Cancer Trials Group Ltd
Australia
1/03/2007 -  Area Director of Clinical Cancer Research Hunter New England Health
Clinical Cancer Research- Oncology
Australia
1/08/1995 -  Senior staff specialist Newcastle Mater Misericordiae Hospital
Medical Oncology
Australia
1/08/1987 - 1/08/1995 Staff Specialist Newcastle Mater Misericordiae Hospital
Medical Oncology
Australia

Awards

Research Award

Year Award
2001 Medical Oncology Group/GSK Travel Award
Medical Oncology Group of Australia

Invitations

Speaker

Year Title / Rationale
2015 Invited Plenary Speaker
Advanced breast cancer International Guidelines (ABC2)
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

Year Citation Altmetrics Link
2003 Ackland S, Beale P, Godefridus J, 'Thymidylate synhase inhibitors', Cancer chemotherapy and Biological response modifiers, Elsevier BV, netherlands 1-28 (2003) [B2]
Citations Scopus - 1

Journal article (118 outputs)

Year Citation Altmetrics Link
2016 Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, et al., 'Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial', Journal of Neuro-Oncology, 128 163-171 (2016)

© 2016, Springer Science+Business Media New York.Newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter has a poor prognosis, with a median survival of 12¿month... [more]

© 2016, Springer Science+Business Media New York.Newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter has a poor prognosis, with a median survival of 12¿months. This phase II study investigated the efficacy and safety of combining the selective integrin inhibitor cilengitide with a combination of metronomic temozolomide and procarbazine for these patients. Eligible patients (newly diagnosed, histologically confirmed supratentorial glioblastoma with unmethylated MGMT promoter) were entered into this multicentre study. Cilengitide (2000¿mg IV twice weekly) was commenced 1¿week prior to radiotherapy combined with daily temozolomide (60¿mg/m2) and procarbazine (50 or 100¿mg) and, after 4¿weeks¿ break, followed by six adjuvant cycles of temozolomide (50¿60¿mg/m2) and procarbazine (50 or 100¿mg) on days 1¿20, every 28¿days. Cilengitide was continued for up to 12¿months or until disease progression or unacceptable toxicity. The primary endpoint for efficacy was a 12-month overall survival rate of 65¿%. Twenty-nine patients completed study treatment. Sixteen patients survived for 12¿months or more, an overall survival rate of 55¿%.¿The median overall survival was 14.5¿months (95¿% CI 11.1¿19.6) and the median progression-free survival was 7.4¿months (95¿% CI 6.1¿8). Cilengitide combined with metronomic temozolomide and procarbazine in MGMT-promoter unmethylated glioblastoma did not improve survival compared with historical data and does not warrant further investigation.

DOI 10.1007/s11060-016-2094-0
2016 Folprecht G, Pericay C, Saunders MP, Thomas A, Lopez Lopez R, Roh JK, et al., 'Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: The AFFIRM study', Annals of Oncology, 27 1273-1279 (2016) [C1]

© The Author 2016.Background: The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (... [more]

© The Author 2016.Background: The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC. Patients and methods: Patients with mCRC were randomized to receive first-line therapy with mFOLFOX6 plus aflibercept (4 mg/kg) or mFOLFOX6 alone. The primary end point of this phase II study was the progression-free survival (PFS) rate at 12 months in each arm. The analysis of efficacy between the arms was a pre-planned secondary analysis. Results: Of 236 randomized patients, 227 and 235 patients were evaluable for the primary efficacy analysis and safety, respectively. The probabilities of being progression-free at 12 months were 25.8% [95% confidence interval (CI) 17.2- 34.4] for the aflibercept/mFOLFOX6 arm and 21.2% (95% CI 12.2-30.3) for the mFOLFOX6 arm. The median PFS was 8.48 months (95% CI 7.89-9.92) for the aflibercept/mFOLFOX6 arm and 8.77 months (95% CI 7.62-9.27) for the mFOLFOX6 arm; the hazard ratio of aflibercept/mFOLFOX6 versus mFOLFOX6 was 1.00 (95% CI 0.74-1.36). The response rates were 49.1% (95% CI 39.7-58.6) and 45.9% (95% CI 36.4-55.7) for patients treated with and without aflibercept, respectively. The most frequent treatment-emergent grade 3/4 adverse events (AEs) excluding laboratory abnormalities reported for aflibercept/mFOLFOX6 versus mFOLFOX6 were neuropathy (16.8% versus 17.2%) and diarrhea (13.4% versus 5.2%). Neutropenia grade 3/4 occurred in 36.1% versus 29.3%. The most common vascular endothelial growth factor inhibition class-effect grade 3/4 AEs for aflibercept/mFOLFOX6 versus mFOLFOX6 were hypertension (35.3% versus 1.7%), proteinuria (9.2% versus 0%), deep vein thrombosis (5.9% versus 0.9%) and pulmonary embolism (5.9% versus 5.2%). Conclusion: No difference in PFS rate was observed between treatment groups. Adding aflibercept to first-line mFOLFOX6 did not increase efficacy but was associated with higher toxicity.

DOI 10.1093/annonc/mdw176
Citations Scopus - 1
2016 McLachlan SA, Fisher RJ, Zalcberg J, Solomon M, Burmeister B, Goldstein D, et al., 'The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04)', European Journal of Cancer, 55 15-26 (2016) [C1]

© 2015 Elsevier Ltd. All rights reserved.Purpose To assess health-related quality of life (HRQOL) in patients participating in a randomised trial of neoadjuvant short course radi... [more]

© 2015 Elsevier Ltd. All rights reserved.Purpose To assess health-related quality of life (HRQOL) in patients participating in a randomised trial of neoadjuvant short course radiation (SC) or long course chemoradiation (LC) for operable rectal cancer. Patients and methods Eligible patients with T3N0-2M0 rectal cancer completed the European Organisation for Research and Treatment of Cancer quality of life questionnaire (QLQ-C30) and the colorectal cancer specific module (QLQ C38) at randomisation and 1, 2, 3, 6, 9 and 12 months later. Results Of 326 patients randomised, 297 (SC 143, LC 154) were eligible for completion of HRQOL questionnaires. Baseline scores were comparable across the SC and LC groups. Patients reported low scores on sexual functioning and sexual enjoyment. Defaecation problems were the worst of the symptoms at baseline. Surgery had the most profoundly negative effect on HRQOL, seen in both the SC and LC treatment groups to the same extent. The most severely affected domains were physical function and role function and the most severely affected symptoms were fatigue, pain, appetite, weight loss and male sexual problems. Most domains and symptoms returned to baseline levels by 12 months apart from body image, sexual enjoyment and male sexual problems. Future perspective was better than prior to treatment. Conclusion There is no overall difference in HRQOL between SC and LC neoadjuvant treatment strategies, in the first 12 months, after surgery. In the immediate postoperative period HRQOL was adversely affected in both groups but for the most part was temporary. Some residual sexual functioning concerns persisted at 12 months.

DOI 10.1016/j.ejca.2015.10.060
Citations Scopus - 1
2016 Fradgley EA, Paul CL, Bryant J, Collins N, Ackland SP, Bellamy D, Levi CR, 'Collaborative Patient-Centered Quality Improvement: A Cross-Sectional Survey Comparing the Types and Numbers of Quality Initiatives Selected by Patients and Health Professionals.', Eval Health Prof, (2016)
DOI 10.1177/0163278716659524
Co-authors Chris Paul, Chris Levi
2016 Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, et al., 'INPP4B is an oncogenic regulator in human colon cancer.', Oncogene, 35 3049-3061 (2016)
DOI 10.1038/onc.2015.361
Co-authors Xu Zhang, Chenchen Jiang, Hubert Hondermarck, Rodney Scott, Rick Thorne
2015 Bryant J, Sanson-Fisher R, Fradgley E, Regan T, Hobden B, Ackland SP, 'Oncology patients overwhelmingly support tissue banking.', BMC Cancer, 15 413 (2015) [C1]
DOI 10.1186/s12885-015-1416-5
Co-authors Rob Sanson-Fisher, Timothy Regan
2014 Yip D, Zalcberg J, Ackland S, Barbour AP, Desai J, Fox S, et al., 'Controversies in the management of gastrointestinal stromal tumors', Asia-Pacific Journal of Clinical Oncology, 10 216-227 (2014) [C1]

Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primar... [more]

Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primary tumors. The Consensus approaches to best practice management of gastrointestinal stromal tumors, published in this journal in 2008, provided guidance for the management of GIST to both clinicians and regulatory authorities. Since then, clinical trials have demonstrated the benefit of adjuvant imatinib in high-risk patients, and mature data from advanced GIST studies suggest that a small but significant proportion of patients with advanced disease can achieve long-term benefit with ongoing imatinib treatment. Other evolving management strategies include the controversial use of palliative or debulking surgery to improve outcomes in advanced GIST and the development of promising new multikinase inhibitors, such as regorafenib, which has established benefit in the third-line setting. This review provides an update of recent developments in GIST management and discusses new controversies that these advances have generated. © 2014 Wiley Publishing Asia Pty Ltd.

DOI 10.1111/ajco.12187
Citations Scopus - 5Web of Science - 3
2013 Ackland S, Goldstein D, McJannett M, 'Forty years of COSA - Contributions to oncology teaching and research', Cancer Forum, 37 238-242 (2013) [C2]
2013 Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, et al., 'Current opinion on optimal treatment for colorectal cancer', EXPERT REVIEW OF ANTICANCER THERAPY, 13 597-611 (2013) [C1]
DOI 10.1586/ERA.13.37
Citations Scopus - 13Web of Science - 13
2013 Ackland S, Fukuda Y, '2012: Year in Review - from dragons to snakes', Asia-Pacific Journal of Clinical Oncology, 9 1-1 (2013) [C3]
DOI 10.1111/ajco.12065
2012 Goldstein D, Spry N, Cummins MM, Brown C, Van Hazel GA, Carroll S, et al., 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106 61-69 (2012) [C1]
Citations Scopus - 4Web of Science - 4
2012 Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al., 'Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04', Journal of Clinical Oncology, 30 3827-3833 (2012) [C1]
Citations Scopus - 161Web of Science - 126
2012 Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, et al., 'Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C', ANNALS OF ONCOLOGY, 23 1531-1536 (2012) [C1]
DOI 10.1093/annonc/mdr488
Citations Scopus - 47Web of Science - 42
2012 Zdenkowski N, Chen S, Van Der Westhuizen A, Ackland S, 'Curative strategies for liver metastases from colorectal cancer: A review', Oncologist, 17 201-211 (2012) [C1]
Citations Scopus - 13Web of Science - 12
2012 Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, Sakoff JA, 'Predicting 5-Fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length - A multivariate analysis', British Journal of Cancer, 107 1525-1533 (2012) [C1]
Citations Scopus - 6Web of Science - 7
Co-authors Lisa Lincz, Jennette Sakoff
2012 Ackland S, Fukuda Y, '2011: Year in review - From rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2012) [C3]
2011 Garg MB, Sakoff JA, Ackland S, 'A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879 2201-2205 (2011) [C1]
Citations Scopus - 6Web of Science - 6
Co-authors Jennette Sakoff
2011 Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, et al., 'A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer', Breast Cancer Research and Treatment, 129 467-476 (2011) [C1]
DOI 10.1007/s10549-011-1471-9
Citations Scopus - 3Web of Science - 2
2011 Ackland S, Fukuda Y, '2011: Year in Review - from rabbits to dragons', Asia-Pacific Journal of Clinical Oncology, 8 1-2 (2011)
DOI 10.1111/j.1743-7563.2012.01538.x
2011 Ackland S, 'Cancer in Australia: A model for other Asia-Pacific countries', Asia-Pacific Journal of Clinical Oncology, 7 323-324 (2011) [C3]
DOI 10.1111/j.1743-7563.2011.01507.x
2011 Agrez M, Garg M, Dorahy D, Ackland S, 'Synergistic anti-tumor effect of cisplatin when combined with an anti-src kinase integrin-based peptide', Journal of Cancer Therapy, 2 295-301 (2011) [C1]
2011 Vilain RE, Dudding TE, Braye SG, Groombridge C, Meldrum C, Spigelman AD, et al., 'Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome?', Clinical Genetics, 79 554-560 (2011) [C3]
DOI 10.1111/j.1399-0004.2010.01489.x
Citations Scopus - 5Web of Science - 3
Co-authors Leonie Ashman, Rodney Scott, Tracy Dudding
2011 Garg MB, Ackland S, 'Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect', Cancer Chemotherapy and Pharmacology, 67 963-966 (2011) [C1]
Citations Scopus - 6Web of Science - 5
2011 Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland S, Van Hazel G, et al., 'Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 67 519-525 (2011) [C1]
Citations Scopus - 6Web of Science - 5
2011 Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al., 'Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)', JOURNAL OF CLINICAL ONCOLOGY, 29 (2011) [E3]
2011 Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland S, Fitzharris B, et al., 'Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer', Journal of Clinical Oncology, 29 4498-4504 (2011) [C1]
Citations Scopus - 50Web of Science - 42
Co-authors John Forbes
2010 Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, Van Hazel GA, et al., 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study', Journal of Clinical Oncology, 28 3191-3198 (2010) [C1]
DOI 10.1200/JCO.2009.27.7723
Citations Scopus - 183Web of Science - 157
2010 De Bock CE, Garg ML, Scott NM, Sakoff JA, Scorgie FE, Ackland S, Lincz L, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, 1-8 (2010) [C1]
DOI 10.1038/tpj.2010.43
Citations Scopus - 10Web of Science - 10
Co-authors Manohar Garg, Lisa Lincz, Jennette Sakoff
2009 Ackland S, Bull JM, Boyle FM, 'Nab-Paclitaxel: A bright new sparc in taxane therapy of cancer', Asia-Pacific Journal of Clinical Oncology, 5 147-150 (2009) [C1]
DOI 10.1111/j.1743-7563.2009.01233.x
Citations Scopus - 1
2009 Ackland S, 'Molecular biomarkers in non-small cell lung cancer: Pointing the way to better outcomes from treatment', Asia-Pacific Journal of Clinical Oncology, 5 213-214 (2009) [C3]
DOI 10.1111/j.1743-7563.2009.01260.x
2009 Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, et al., 'Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer', ONCOLOGY, 77 113-119 (2009) [C1]
DOI 10.1159/000229787
Citations Scopus - 96Web of Science - 83
2008 Ackland S, Tracey E, 'Cancer registries: Their role in health care delivery in the Asia-Pacific region', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 4 71-74 (2008) [C3]
DOI 10.1111/j.1743-7563.2008.00160.x
Citations Scopus - 1Web of Science - 1
2008 Vilain RE, Ackland S, 'Gastrointestinal stromal tumors - A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?', Asia-Pacific Journal of Clinical Oncology, 4 185-187 (2008) [C3]
2008 Hill TA, Stewart SG, Gordon CP, Ackland SR, Gilbert J, Sauer B, et al., 'Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition', ChemMedChem, 3 1878-1892 (2008) [C1]
DOI 10.1002/cmdc.200800192
Citations Scopus - 40Web of Science - 41
Co-authors Adam Mccluskey, Jennette Sakoff
2007 Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity', Bioorganic and Medicinal Chemistry Letters, 17 3392-3397 (2007) [C1]
DOI 10.1016/j.bmcl.2007.03.093
Citations Scopus - 56Web of Science - 48
Co-authors Adam Mccluskey, Jennette Sakoff
2007 Hill TA, Stewart SG, Ackland S, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation', Bioorganic and Medicinal Chemistry, 15 6126-6134 (2007) [C1]
DOI 10.1016/j.bmc.2007.06.034
Citations Scopus - 59Web of Science - 52
Co-authors Adam Mccluskey, Jennette Sakoff
2007 Stewart SG, Hill TA, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity', Bioorganic and Medicinal Chemistry, 15 7301-7310 (2007) [C1]
DOI 10.1016/j.bmc.2007.08.028
Citations Scopus - 37Web of Science - 28
Co-authors Jennette Sakoff, Adam Mccluskey
2007 Temmink OH, Hoebe EK, Van Der Born K, Ackland S, Fukushima M, Peters GJ, 'Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells', British Journal of Cancer, 96 231-240 (2007) [C1]
DOI 10.1038/sj.bjc.6603549
Citations Scopus - 25Web of Science - 19
2007 Lincz L, Scorgie FE, Garg MB, Ackland S, 'Identification of a novel single nucleotide polymorphism in the second tandem repeat sequence of the thymidylate synthase 2R allele', International Journal of Cancer, 120 1930-1934 (2007) [C1]
DOI 10.1002/ijc.22568
Citations Scopus - 31Web of Science - 27
Co-authors Lisa Lincz
2007 Lincz L, Scorgie FE, Garg ML, Ackland S, 'Reply to the letter to the editor 'Classification of thymidylate synthase gene enhancer region polymorphisms'', International Journal of Cancer, 121 2581-2582 (2007) [C3]
DOI 10.1002/ijc.22987
Co-authors Manohar Garg, Lisa Lincz
2007 Young JM, Leong DC, Armstrong K, O'Connell D, Armstrong BK, Spigelman AD, et al., 'Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study', Medical Journal of Australia, 186 292-295 (2007) [C1]
Citations Scopus - 22Web of Science - 19
2007 Carrington C, Carlton J, Ackland S, 'Preventing chemotherapy errors: Implementing system changes', Asia-Pacific Journal of Clinical Oncology, 3 57-58 (2007) [C3]
2007 Davis AJ, Brew S, Gebski VJ, Lewis CR, Moylan E, Parnis FX, Ackland S, 'Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 3 37-43 (2007) [C1]
DOI 10.1111/j.1743-7563.2006.00083.x
Citations Scopus - 5Web of Science - 3
2007 Findlay M, Sharples K, Riley GA, Simpson A, Ackland S, Hall K, et al., 'Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer', Asia-Pacific Journal of Clinical Oncology, 3 99-105 (2007) [C1]
DOI 10.1111/j.1743-7563.2007.00095.x
Citations Scopus - 5Web of Science - 5
2006 Goldstein D, Ackland S, Bell DR, Olver IN, Davis ID, Rosenthal MA, et al., 'Phase II study of vinflunine in patients with metastatic renal cell carcinoma', Investigational New Drugs, 24 429-434 (2006) [C1]
DOI 10.1007/s10637-006-6437-0
Citations Scopus - 15Web of Science - 9
2006 Wong M, Balleine RL, Blair EYL, McLachlan AJ, Ackland S, Garg M, et al., 'Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer', Journal of Clinical Oncology, 24 2448-2455 (2006) [C1]
DOI 10.1200/JCO.2005.02.1295
Citations Scopus - 44Web of Science - 37
2006 Ackland S, 'Cervical carcinoma: A common and preventable problem in developing countries (Editorial)', Asia-Pacific Journal of Clinical Oncology, 2 69-70 (2006) [C3]
Citations Scopus - 1
2006 Ackland S, Clarke SJ, Beale P, Peters GJ, 'Thymidylate synthase inhibitors', Update on Cancer Therapeutics, 1 403-427 (2006) [C1]
DOI 10.1016/j.uct.2006.09.001
Citations Scopus - 10
2005 Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, et al., 'A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer', British Journal of Cancer, 93 1236-1243 (2005) [C1]
DOI 10.1038/sj.bjc.6602841
Citations Scopus - 33Web of Science - 28
2005 Odelli C, Burgess D, Bateman L, Hughes A, Ackland S, Gillies J, Collins CE, 'Nutrition Support Improves Patient Outcomes, Treatment Tolerance and Admission Characteristics in Oesophageal Cancer', Clinical Oncology, 17 639-645 (2005) [C1]
DOI 10.1016/j.clon.2005.03.015
Citations Scopus - 56Web of Science - 41
Co-authors Clare Collins
2005 Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al., 'Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial', Lancet Oncology, 6 659-668 (2005) [C1]
DOI 10.1016/s1470-2045(05)70288-6
Citations Scopus - 523Web of Science - 403
Co-authors Jim Denham
2004 Lincz L, Scorgie F, Sakoff J, Fagan K, Ackland S, Enno A, 'Telomere length predicts neutrophil recovery in absence of G-CSF after autologous peripheral blood stem cell transplantation', Bone Marrow Transplant, 34 439-445 (2004) [C1]
DOI 10.1038/sj.bmt.1704607
Citations Scopus - 3Web of Science - 3
Co-authors Lisa Lincz, Jennette Sakoff
2004 Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, et al., 'Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients', Clinical and Experimental Pharmacology and Physiology, 31 677-682 (2004) [C1]
DOI 10.1111/j.1440-1681.2004.03065.x
Citations Scopus - 8Web of Science - 8
2004 Sakoff JA, Howitt IJ, Ackland S, McCluskey A, 'Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition', Cancer Chemotherapy and Pharmacology, 53 225-232 (2004) [C1]
DOI 10.1007/s00280-003-0730-9
Citations Scopus - 8Web of Science - 7
Co-authors Jennette Sakoff, Adam Mccluskey
2004 O'Brien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al., 'Reduced cardiotoxicity and comparable efficacy in a phase 3 trial of pegylated liposomal doxorubicine HCI (CAELYX / Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer', Annals of Oncology, 15 440-449 (2004) [C1]
DOI 10.1093/annonc/mdh097
Citations Scopus - 675Web of Science - 513
2003 Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al., 'A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy', Annals of Oncology, 14 29-35 (2003)

Background: We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administratio... [more]

Background: We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administration of filgrastim, in the provision of neutrophil support. Patients and methods: Patients (n = 157) were randomized to receive either a single 6 mg subcutaneous (s.c.) injection of pegfilgrastim or daily 5 mg/kg s.c. injections of filgrastim, after doxorubicin and docetaxel chemotherapy (60 mg/m2 and 75 mg/m2, respectively). Duration of grade 4 neutropenia, depth of neutrophil nadir, incidence of febrile neutropenia, time to neutrophil recovery and safety information were recorded. Results: A single 6 mg injection of pegfilgrastim was as effective as daily injections of filgrastim for all efficacy measures for all cycles. The mean duration of grade 4 neutropenia in cycle 1 was 1.8 and 1.6 days for the pegfilgrastim and filgrastim groups, respectively. Results for all efficacy end points in cycles 2-4 were consistent with the results from cycle 1. A trend towards a lower incidence of febrile neutropenia was noted across all cycles with pegfilgrastim compared with filgrastim (13% versus 20%, respectively). A single fixed dose of pegfilgrastim was as safe and well tolerated as standard daily filgrastim. Conclusions: A single fixed dose of pegfilgrastim administered once per cycle of chemotherapy was comparable to multiple daily injections of filgrastim in safely providing neutrophil support during myelosuppressive chemotherapy. Pegfilgrastim may have utility in other clinical settings of neutropenia.

DOI 10.1093/annonc/mdg019
Citations Scopus - 368
2003 Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31 68-79 (2003) [C1]
DOI 10.1016/S0045-2068(02)00524-2
Citations Scopus - 78Web of Science - 62
Co-authors Adam Mccluskey, Michael Bowyer, Jennette Sakoff
2003 Denham J, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lam D, et al., 'Relapse patterns after chemo-radiation for carcinoma of the oesophagus', Clinical Oncology, 15 98-108 (2003) [C1]
DOI 10.1053/clon.2003.0212
Citations Scopus - 39Web of Science - 32
Co-authors Jim Denham, Allison Steigler
2002 Sakoff J, Ackland S, Baldwin ML, Atherton MA, McCluskey A, 'Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues', Investigational New Drugs, 20 1-11 (2002) [C1]
Citations Scopus - 65Web of Science - 54
Co-authors Mirella Atherton, Jennette Sakoff, Adam Mccluskey
2002 Ackland SP, Clarke SJ, Beale P, Peters GJ, 'Thymidylate synthase inhibitors.', Cancer chemotherapy and biological response modifiers, 20 1-36 (2002)
Citations Scopus - 8
2002 Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Milward MJ, Ackland S, 'Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na¿ve patients with advanced non-small-cell lung cancer', Annals of Oncology, 13 737-741 (2002) [C1]
Citations Scopus - 110Web of Science - 72
2002 Rischin D, Ackland S, Smith J, Garg MB, Clarke SJ, Millward MJ, et al., 'Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with G-CSF but not with prophylactic antibiotics', Annals of Oncology, 13 1810-1818 (2002) [C1]
Citations Scopus - 11Web of Science - 11
2002 McCluskey A, Ackland S, Gardiner E, Walkom CC, Sakoff J, 'The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16 291-303 (2002) [C1]
Citations Scopus - 28Web of Science - 23
Co-authors Jennette Sakoff, Adam Mccluskey
2002 Garg MB, Sevester JC, Sakoff JA, Ackland SP, 'Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity', JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 774 223-230 (2002)
DOI 10.1016/S1570-0232(02)00239-8
Citations Scopus - 38Web of Science - 31
Co-authors Jennette Sakoff
2002 Garg MB, Sevester JC, Sakoff JA, Ackland S, 'Rapid and simple chromatographic method for the determination of uracil and dihydrouracil plasma levels: A potential pretreatment predictor of 5FU toxicity', Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Science, 774 223-230 (2002) [C1]
2002 Sakoff J, De Waal E, Garg M, Denham J, Scorgie F, Enno A, et al., 'Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood', Leukemia and Lymphoma, 43(10) 2017-2020 (2002) [C1]
Citations Scopus - 23Web of Science - 23
Co-authors Jennette Sakoff, Jim Denham, Lisa Lincz
2002 Marx G, Lewis C, Hall K, Levi J, Ackland S, 'Phase I study of docetaxel plus ifosfamide in patients with advanced cancer', British Journal of Cancer, 87 846-849 (2002) [C1]
Citations Scopus - 5Web of Science - 4
2002 Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, et al., 'Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines', British Journal of Cancer, 86 1367-1372 (2002) [C1]
Citations Scopus - 150Web of Science - 118
2001 Ackland S, Anton A, Breitbach G, Colajori E, Tursi J, Delfino C, et al., 'Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophoshamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study', Journal of Clinical Oncology, 19 943-953 (2001) [C1]
Citations Scopus - 38Web of Science - 32
2001 McCluskey A, Walkom CC, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters, 11 2941-2946 (2001) [C1]
Citations Scopus - 60Web of Science - 55
Co-authors Adam Mccluskey, Michael Bowyer, Jennette Sakoff
2000 Sanson-Fisher RW, Girgis A, Boyes A, Bonevski B, Burton L, Cook P, et al., 'The unmet supportive care needs of patients with cancer', Cancer, 88 225-236 (2000) [C1]
Citations Scopus - 280Web of Science - 337
Co-authors Allison Boyes, Rob Sanson-Fisher, Billie Bonevski
2000 Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al., 'Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.', NEW ENGLAND JOURNAL OF MEDICINE, 343 905-914 (2000)
DOI 10.1056/NEJM200009283431302
Citations Scopus - 2485Web of Science - 1996
2000 Peters G, De Bruin M, Fukushima M, Van Triest B, Hoekman K, Pinedo H, Ackland S, 'Thymidine phosphorylase in angiogenesis and drug resistance', Advances in Experimental Medicine and Biology, 486 291-294 (2000) [C2]
2000 Peters GJ, van der Wilt CL, van Moorsel CJA, Kroep JR, Bergman AM, Ackland SP, 'Basis for effective combination cancer chemotherapy with antimetabolites', PHARMACOLOGY & THERAPEUTICS, 87 227-253 (2000)
DOI 10.1016/S0163-7258(00)00086-3
Citations Scopus - 171Web of Science - 163
2000 Sakoff J, Ackland S, 'Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells', Cancer Chemotherapy and Pharmacology, 46 477-487 (2000) [C1]
Citations Scopus - 30Web of Science - 27
Co-authors Jennette Sakoff
2000 Garg M, Ackland S, 'Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine', Journal of Chromatography B, 748 383-388 (2000) [C1]
Citations Scopus - 50Web of Science - 46
2000 Sakoff JA, McCluskey A, Sims ATR, Stewart JF, Ackland SP, 'A counter intuitive therapy for the treatment of cancer: Inhibition of protein phosphatases 1 and 2A by cantharidin (Spanish Fly) analogues.', CLINICAL CANCER RESEARCH, 6 4495S-4495S (2000)
Co-authors Jennette Sakoff, Adam Mccluskey
2000 Bonevski B, Sanson-Fisher RW, Girgis A, Burton L, Cook P, Boyes A, et al., 'Evaluation of an instrument to assess the needs of patients with cancer', Cancer, 88 217-225 (2000) [C1]
Citations Scopus - 249Web of Science - 201
Co-authors Allison Boyes, Billie Bonevski, Rob Sanson-Fisher
1999 Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MHN, Olver IN, et al., 'Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer', Journal of Clinical Oncology, 17 2355-2364 (1999)

Purpose: To determine the place of single-agent paclitaxel compared with nonanthracycline combination chemotherapy as front-line therapy in metastatic breast cancer. Patients and ... [more]

Purpose: To determine the place of single-agent paclitaxel compared with nonanthracycline combination chemotherapy as front-line therapy in metastatic breast cancer. Patients and Methods: Patients with previously untreated metastatic breast cancer were randomized to receive either paclitaxel 200 mg/m2 intravenously (IV) over 3 hours for eight cycles (24 weeks) or standard cyclophosphamide 100 mg/m2/d orally on days 1 to 14, methotrexate 40 mg/m2 IV on days 1 and 8, fluorouracil 600 mg/m2 IV on days 1 and 8, and prednisone 40 mg/m2/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin recommended as second-line therapy. Results: A total of 209 eligible patients were randomized with a median survival duration of 17.3 months for paclitaxel and 13.9 months for CMFP. Multivariate analysis showed that patients who received paclitaxel survived significantly longer than those who received CMFP (P = .025). Paclitaxel produced significantly less severe leukopenia, thrombocytopenia, mucositis, documented infections (all P < .001), nausea or vomiting (P = .003), and fever without documented infection (P = .007), and less hospitalization for febrile neutropenia than did CMFP (P = .001). Alopecia, peripheral neuropathy, and myalgia or arthralgia were more severe with paclitaxel (all P < .0001). Overall, quality of life was similar for both treatments (P = .07). Conclusion: Initial paclitaxel was associated with significantly less myelosuppression and fewer infections, with longer survival and similar quality of life and control of metastatic breast cancer compared with CMFP.

Citations Scopus - 172
1999 Ackland SP, Peters GJ, 'Erratum: Thymidine phosphorylase: Its role in sensitivity and resistance to anticancer drugs (Drug Resistance Updates (1999) 2 (205-214))', Drug Resistance Updates, 2 345 (1999)
1999 Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, et al., 'Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer', Australasian Radiology, 43 220-226 (1999)

The purpose of the present paper was to evaluate treatment outcome after conservative breast surgery or mastectomy followed by simultaneous adjuvant radiotherapy and cyclophospham... [more]

The purpose of the present paper was to evaluate treatment outcome after conservative breast surgery or mastectomy followed by simultaneous adjuvant radiotherapy and cyclophosphamide, methotrexate and fluorouracil (CMF) therapy. Two hundred and sixty eight (268) patients were treated at two Australian and two New Zealand centres between 1981 and July 1995. One hundred and sixty-nine patients underwent conservation surgery and 99 had mastectomies. Median follow-up was 53 months. Conventionally fractionated radiation was delivered simultaneously during the first two cycles of CMF, avoiding radiation on the Fridays that the intravenous components of CMF were delivered. In conservatively treated patients, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 34.5 ± 5.2%, 25.4 ± 4.5% and 75.5 ± 4.8%, respectively. Crude incidence of local relapse at 4 years was 6.3% and at regional/distant sites was 26.3%. Highest grades of granulocyte toxicity (< 0.5 x 109/L), moist desquamation, radiation pneumonitis and persistent breast oedema were recorded in 10.7, 8.5, 8.9 and 17.2%, respectively. In patients treated by mastectomy, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 59.7 ± 7.3%, 56.7 ± 7.4% and 50.1 ± 7%. The crude incidence of local relapse at 4 years was 5.6% and at regional/distant sites it was 45.7%. The issue of appropriate timing of adjuvant therapies has become particularly important with the increasing acknowledgement of the value of anthracycline-based regimens. For women in lower risk categories (e.g. 1-3 nodes positive or node negative), CMF may offer a potentially better therapy, particularly where breast-conserving surgical techniques have been used. In such cases CMF allows the simultaneous delivery of radiotherapy with the result of optimum local control, without compromise or regional or systemic relapse rates. Further randomized trials that directly address the optimal integration of the two modalities, such as the one carried out in Boston, are clearly necessary.

DOI 10.1046/j.1440-1673.1999.00638.x
Citations Scopus - 12
Co-authors Jim Denham
1999 Denham JW, Ackland SP, Burmeister B, Walpole E, Lamb DS, Dady P, Spry NA, 'Causes for increased myelosuppression with increasing age in patients with oesophageal cancer treated by chemoradiotherapy', EUROPEAN JOURNAL OF CANCER, 35 921-927 (1999)
DOI 10.1016/S0959-8049(99)00065-9
Citations Scopus - 5Web of Science - 4
Co-authors Jim Denham
1999 Ackland S, Rischin D, Beith J, Gupta S, Wyatt S, Davison J, et al., 'Phase I study of docetaxel epirubicin and cyclophosphamide (TEC) in patients with advanced cancer (AC)', EUROPEAN JOURNAL OF CANCER, 35 S292-S292 (1999)
DOI 10.1016/S0959-8049(99)81594-9
1999 Newell SA, Sanson-Fisher RW, Girgis A, Ackland S, 'The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study', European Journal of Cancer Care, 8 73-82 (1999) [C1]
Citations Scopus - 57Web of Science - 47
Co-authors Rob Sanson-Fisher
1999 Ackland SP, Peters GJ, 'Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs', DRUG RESISTANCE UPDATES, 2 205-214 (1999)
DOI 10.1054/drup.1999.0089
Citations Scopus - 40Web of Science - 37
1998 van der Heijden M, Ackland SP, Deveridge S, 'Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy - A case report and review of the literature', ACTA ONCOLOGICA, 37 107-109 (1998)
Citations Scopus - 12Web of Science - 16
1998 Ackland SP, 'Drug treatment of breast cancer', Australian Prescriber, 21 15-19 (1998)

The medical treatments available for breast cancer include endocrine agents, cytotoxic chemotherapy and adjunctive treatments. New antioestrogens and aromatase inhibitors offer a ... [more]

The medical treatments available for breast cancer include endocrine agents, cytotoxic chemotherapy and adjunctive treatments. New antioestrogens and aromatase inhibitors offer a greater breadth of endocrine therapy and lower toxicity than some older drugs. Anthracyclines (doxorubicin or epirubicin) are now the major components of first-line combination chemotherapy. Many new cytotoxic drugs are currently undergoing phase III clinical trials and may ultimately find a role in the management of advanced disease, In adjuvant therapy of early breast cancer, either hormonal therapy, chemotherapy or both are needed to provide optimal reduction of the risk ofrecurrence.

1998 Gurney HP, Ackland S, Gebski V, Farrell G, 'Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation', JOURNAL OF CLINICAL ONCOLOGY, 16 2299-2304 (1998)
Citations Scopus - 91Web of Science - 80
1998 Garg M, Ackland S, 'A sensitive method for the determination of docetaxel (Taxotere (R)) in human plasma by high performance liquid chromatography', ANNALS OF ONCOLOGY, 9 94-94 (1998)
1998 Ackland S, Garg M, van Moorsel CJA, Kuiper CM, Smid K, Peters GJ, 'Tomudex and cisplatin have additive cytotoxicity and no biochemical interaction in ovarian cancer cell lines', ANNALS OF ONCOLOGY, 9 155-155 (1998)
1998 Clarke S, Millward M, Findlay M, Ackland S, Hosie D, Abratt R, Goedhals L, 'Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC)', ANNALS OF ONCOLOGY, 9 86-87 (1998)
Citations Web of Science - 13
1998 van Laar JAM, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ, 'Comparison of 5-fluoro-2 '-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer', EUROPEAN JOURNAL OF CANCER, 34 296-306 (1998)
DOI 10.1016/S0959-8049(97)00366-3
Citations Scopus - 78Web of Science - 68
1997 Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, et al., 'A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: Preliminary results', SEMINARS IN ONCOLOGY, 24 5-9 (1997)
Citations Web of Science - 2
1997 Ackland SP, Garg MB, Dunstan RH, 'Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography', ANALYTICAL BIOCHEMISTRY, 246 79-85 (1997)
DOI 10.1006/abio.1996.9943
Citations Scopus - 35Web of Science - 34
Co-authors Hugh Dunstan
1997 Leong DCS, Kinlay S, Ackland S, Bonaventura A, Stewart JF, 'Low-risk febrile neutropenia in a medical oncology unit', AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 27 403-407 (1997)
DOI 10.1111/j.1445-5994.1997.tb02199.x
Citations Scopus - 11Web of Science - 6
1997 Liu JP, Yajima Y, Li H, Ackland S, Akita Y, Stewart J, Kawashima S, 'Molecular interactions between dynamin and G-protein beta gamma-subunits in neuroendocrine cells', MOLECULAR AND CELLULAR ENDOCRINOLOGY, 132 61-71 (1997)
DOI 10.1016/S0303-7207(97)00120-2
Citations Scopus - 18Web of Science - 19
1997 Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, et al., 'Paclitaxel as first-line treatment for metastatic breast cancer', ONCOLOGY, 11 19-23 (1997)

When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to com... [more]

When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to compare paclitaxel with standard chemotherapy as front-line therapy for this disease. Patients with measurable or evaluable metastatic breast cancer, no prior chemotherapy for metastatic disease, and an Eastern Cooperative Oncology Group performance status of 0 to 2 were randomized to receive paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles (6 months) or standard treatment with oral cyclophosphamide (Cytoxan) 100 mg/m2/d days 1 through 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5-fluorouracil 600 mg/m2 days 1 and 8, and oral prednisolone 40 mg/m2/d (CMFP) days 1 through 14 for six cycles (6 months). Patients whose disease progressed or relapsed were recommended to receive second-line epirubicin. Accrual has been completed with 208 patients randomized, but a preplanned interim analysis of the first 100 patients is reported here. Analysis of quality of life, assessed by a linear analogue scale and overall quality of life indices, is ongoing. Objective response occurred in 31% (confidence interval, 19% to 45%) with paclitaxel and 35% (confidence interval, 22% to 51%) with CMFP with stable disease in an additional 33% and 29%, respectively. Median time to progression was 5.5 months for paclitaxel-treated patients and 6.4 months for those given CMFP, with median survival durations of 17.3 and 11.3 months, respectively. Grades 3 and 4 neutropenia occurred in 64% of patients treated with paclitaxel and in 63% treated with CMFP. However, febrile neutropenia was the primary reason for hospitalization in 1% of paclitaxel courses, compared with 8% of CMFP courses. Nine percent of the patients had major infections with CMFP, but none were seen with paclitaxel. Moderate or severe mucositis occurred in 13% of paclitaxel-treated and 27% of CMFP-treated patients. Alopecia and peripheral neuropathy were more common with paclitaxel Quality of life assessments in the first 100 patients suggest better overall results on paclitaxel treatment as compared with CMFP. Preliminary analyses suggest that single-agent paclitaxel is well tolerated and provides comparable control of metastatic cancer to CMFP combination therapy when used as front-line treatment.

Citations Scopus - 17
1996 Peters GJ, Ackland SP, 'New antimetabolites in preclinical and clinical development', Expert Opinion on Investigational Drugs, 5 637-679 (1996)

A number of new antimetabolites successfully entered clinical practice over the last ten years, and several more are awaiting registration in a number of countries. In addition, s... [more]

A number of new antimetabolites successfully entered clinical practice over the last ten years, and several more are awaiting registration in a number of countries. In addition, several compounds have been developed for use in combination with established anticancer agents (primarily 5-fluorouracil [5-FU] or one of its analogues). The most successful group of new anticancer agents are the deoxynucleoside analogues (e.g., cladribine, fludarabine, 5-aza-2'-deoxycytidine and gemcitabine), which require activation by one of the four deoxynucleoside kinases present in mammalian cells. However, a further analogue, pentostatin, is a potent inhibitor of adenosine deaminase, leading to an increase in deoxyadenosine, which becomes toxic after conversion to the deoxynucleotide. Other interesting compounds require activation by a viral deoxynucleoside kinase; the Herpes Simplex Virus (HSV)-thymidine kinase (TK), e.g., ganciclovir. A number of compounds have been developed to modulate the activity of 5-FU, e.g., ethynyluracil (EU) and 5-chloro-2,4- dihydroxypyridine (CDHP) inhibit dihydropyrimidine dehydrogenase (DPD), thus, preventing degradation of 5-FU and increasing its bioavailability. Prodrugs of 5-FU have attracted much more attention recently than in the 1980s: e.g., ftorafur, present in (UFT) [1-(2-tetrahydrofuryl)-5-fluorouracil:uracil (1:4)] and S-1, and capecitabine, a prodrug of the 5-FU precursor 5'-deoxy-5- fluorouridine. Antifolates have also received a lot of attention and several new antifolates have been developed over the last ten years, of which the most interesting are the new thymidylate synthase (TS) inhibitors. Many of these have entered clinical development and some have even been registered (e.g., tomudex in England). These compounds include tomudex (ZD1694, formerly ICI-D1694; Zeneca), LY231514 (Eli Lilly), 1843U89 (formerly BW1843U89; Glaxo Wellcome), and AG331 and AG337 (Thymitaq; Agouron). AG337 is of special interest, since it appears to exhibit a different pattern of activity to that of tomudex. A new group of antifolates in development, and generating considerable interest, are the glycinamide ribonucleotide transferase (GARTF) inhibitors: e.g., lometrexol and LY309887 (Eli Lilly), and AG2032 and AG2034 (Agouron). However, the place of these compounds in therapy (i.e., as single agents or as modulating agents) remains unclear at present. In summary, rational drug design over the last few decades has led to the introduction of a number of antimetabolites with significant antitumour activity not only against leukaemia, but also against several solid tumours. © 1996 Ashley Publications Ltd.

DOI 10.1517/13543784.5.6.637
Citations Scopus - 56
1996 Cunningham D, Zalcberg JR, Rath U, Oliver I, Van Cutsem E, Svensson C, et al., 'Final results of a randomised trial comparing 'Tomudex'® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer', Annals of Oncology, 7 961-965 (1996)
Citations Scopus - 205
1995 DENHAM JW, HAMILTON CS, CHRISTIE D, OBRIEN M, BONAVENTURA A, STEWART JF, et al., 'SIMULTANEOUS ADJUVANT RADIATION-THERAPY AND CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER - TOXICITY AND DOSE MODIFICATION - A TRANS-TASMAN RADIATION ONCOLOGY GROUP MULTI-INSTITUTION STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 31 305-313 (1995)
DOI 10.1016/0360-3016(94)E0065-R
Citations Scopus - 28Web of Science - 23
Co-authors Jim Denham
1995 BURMEISTER BH, DENHAM JW, OBRIEN M, JAMIESON GG, GILL PG, DEVITT P, et al., 'COMBINED-MODALITY THERAPY FOR ESOPHAGEAL-CARCINOMA - PRELIMINARY-RESULTS FROM A LARGE AUSTRALASIAN MULTICENTER STUDY', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32 997-1006 (1995)
DOI 10.1016/0360-3016(94)00449-U
Citations Scopus - 52Web of Science - 45
Co-authors Jim Denham
1993 Ackland SP, Hamilton CS, Joseph DJ, Denham JW, 'Phase I/II study of concurrent weekly carboplatin and radiation therapy in advanced head and neck cancer', Clinical Oncology, 5 133-138 (1993)

Thirty-two patients with locally advanced head and neck cancer have been treated with concurrent weekly carboplatin and conventional radiation therapy (RT) (2 Gy fractions 4-5 day... [more]

Thirty-two patients with locally advanced head and neck cancer have been treated with concurrent weekly carboplatin and conventional radiation therapy (RT) (2 Gy fractions 4-5 days/week to a total dose of 64-70 Gy over 7-8 weeks) in a Phase I/II study. Carboplatin was administered weekly during RT at doses of 75-150 mg/m2//wk as a 1-hour infusion. The maximum tolerated dose of carboplatin was 130 mg/m2//wk, with myelosuppression, predominantly neutropenia, being dose limiting. Other systemic toxicities were insignificant and no overlapping toxicity was evident. Ultimate locoregional control and survival probabilities were disappointing. It is suggested that either further studies using radiation and carboplatin at the dose 130 mg/m2//wk, or variations on dose and scheduling be performed prior to the instigation of Phase III studies. © 1993 The Royal College of Radiologists.

DOI 10.1016/S0936-6555(05)80307-3
Citations Scopus - 5
Co-authors Jim Denham
1993 Cooper SG, Bonaventura A, Ackland SP, Joseph DJ, Stewart JF, Hamilton CS, Denham JW, 'Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: A phase II study', Clinical Oncology, 5 169-173 (1993)

Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival. We wished to find out if we could safely give concurrent ra... [more]

Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival. We wished to find out if we could safely give concurrent radiotherapy and 5-fluorouracil (5-FU) modulated by leucovorin (LV) in 3 settings: pre-operatively, adjuvantly and in recurrent disease. A total of 39 patients were treated, 11 preoper-atively, 17 adjuvantly and 11 with recurrent disease. There were 26 males and 13 females with a median age of 64 years. The median radiotherapy (RT) dose was 45 Gy/25 fractions/1.8 Gy per fraction (range 25-63 Gy). Chemotherapy consisted of LV 80 mg/m2 i.v. infusion over 1.5 hours followed by 5-FU 400 mg/m2 i.v. bolus, both given once a week. The median number of cycles was 8 (range 3-12). Diarrhoea was the main toxicity, and was encountered in 30 patients (77%): grade 1 in 3 (8%), grade 2 in 12 (30%), grade 3 in 11 (28%), and grade 4 in 4 (10%). This required 18 (46%) patients to have modifications to their RT (20% had breaks and 26% ceased at doses <45 Gy). Nine patients (23%) had modifications in the chemotherapy (10% had breaks and 13% received <6 cycles). Encouraging responses were seen in the preoperative setting. Concurrent RT and 5-FU/LV, as given in this schedule, results in an unacceptable incidence of diarrhoea, limiting both the total dose of RT and chemotherapy that can be delivered, particulary in patients who have had previous surgery. © 1993 The Royal College of Radiologists.

DOI 10.1016/S0936-6555(05)80319-X
Citations Scopus - 12
Co-authors Jim Denham
1992 Rosenthal MA, Raghavan D, Stuart-Harris R, Ackland S, Grygiel J, 'The treatment of disseminated prostate cancer with estramustine', Australian and New Zealand Journal of Surgery, 62 871-873 (1992)

Forty-three patients with disseminated prostate cancer, resistant to orchidectomy or hormone therapy with estramustine were treated. Of the 33 evaluable patients, three patients h... [more]

Forty-three patients with disseminated prostate cancer, resistant to orchidectomy or hormone therapy with estramustine were treated. Of the 33 evaluable patients, three patients had stable disease and two had a partial tumour response according to National Prostatic Cancer Project criteria. Twenty-five patients (58%) showed improvement in pain and urinary symptoms. Ten patients (23%) had side effects requiring cessation of therapy. These results show that estramustine has a limited role in the treatment of advanced prostate cancer and that therapy is frequently associated with intolerable side effects.

Citations Scopus - 1
1990 JOSEPH DJ, HAMILTON CS, DENHAM JW, ACKLAND SP, STEWART JF, 'WHITHER SCREENING MAMMOGRAPHY IN AUSTRALIA - ESTABLISHING A SATISFACTORY BASIS FOR FUNDING', MEDICAL JOURNAL OF AUSTRALIA, 152 545-546 (1990)
Co-authors Jim Denham
1989 Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M, Sinkule JA, 'Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin', Clinical Pharmacology and Therapeutics, 45 340-347 (1989)

Steady-state plasma levels of doxorubicin and doxorubicinol were analyzed in 32 patients with advanced cancer, each of whom was given doxorubicin by long-term continuous infusion ... [more]

Steady-state plasma levels of doxorubicin and doxorubicinol were analyzed in 32 patients with advanced cancer, each of whom was given doxorubicin by long-term continuous infusion at progressively increasing infusion rates. Patients received doxorubicin for 2 to 50 weeks at rates of 0.2 to 6.1 mg/m2/day. Dose-limiting stomatitis and leukopenia were observed. The mean maximum steady state doxorubicin concentration was 6.04 ng/ml at a mean maximum infusion rate of 3.92 mg/m2/day. Clearance mechanisms did not appear to be saturated at the durations or infusion rates used in this study. The maximum steady-state doxorubicin level and the In (initial WBC) were significant correlates of the In nadir WBC) (p = 0.002 and 0.02, respectively). A model was constructed according to these two parameters that significantly describes In (nadir WBC) (p = 0.001). Neither age, infusion rate, nor doxorubicinol level correlated with nadir WBC. Stomatitis did not correlate with any of these parameters. The demonstration of this pharmacodynamic relationship highlights the potential importance of pharmacologic data collection in ongoing attempts to predict the clinical effects of anticancer drugs. © 1989.

Citations Scopus - 61
1989 COOPER SG, DENHAM JW, HAMILTON CS, JOSEPH DJ, STEWART JF, ACKLAND SP, 'THE PRICE OF A FALSE-NEGATIVE RESULT OF MAMMOGRAPHY AND AN OVERENTHUSIASTIC LAY PRESS', MEDICAL JOURNAL OF AUSTRALIA, 150 664-664 (1989)
Citations Web of Science - 1
Co-authors Jim Denham
1988 Ackland SP, Bur ME, Adler SS, Robertson M, Baron JM, 'White blood cell aplasia associated with thymoma', American Journal of Clinical Pathology, 89 260-263 (1988)

A limited number of cases of acquired hypoplastic neutropenia or pure white blood cell aplasia (PWCA) associated with thymoma have been reported, in contrast to the well-documente... [more]

A limited number of cases of acquired hypoplastic neutropenia or pure white blood cell aplasia (PWCA) associated with thymoma have been reported, in contrast to the well-documented association of pure red blood cell aplasia and thymoma. The mechanism of the aplasia in these disorders is unclear. The authors report a case of PWCA (with total absence of all granulopoietic elements in the bone marrow) in a patient with metastatic spindle cell thymoma, in which suppression of autologous granulocyte-macrophage colony-forming units by the patient's serum could be demonstrated. This finding suggests a humoral autoimmune mechanism for the pathogenesis of PWCA in this patient and lends support to the possibility that all hematologic phenomena associated with thymoma may have an autoimmune basis.

Citations Scopus - 12
1988 Ackland SP, Schilsky RL, Beckett MA, Weichselbaum RR, 'Synergistic cytotoxicity and DNA strand break formation by bromodeoxyuridine and bleomycin in human tumor cells', Cancer Research, 48 4244-4249 (1988)

5-Bromo-2'-deoxyuridine (BrdUrd) is a thymidine analogue whose cellular effects are related to its incorporation into DNA. BrdUrd is a known radiosensitizing agent that could pote... [more]

5-Bromo-2'-deoxyuridine (BrdUrd) is a thymidine analogue whose cellular effects are related to its incorporation into DNA. BrdUrd is a known radiosensitizing agent that could potentially enhance the activity of chemotherapeutic agents that interact directly with DNA. Therefore we studied the interaction of BrdUrd and bleomycin in a human head and neck squamous carcinoma cell line, SQ20B. Using a colony-forming assay and analyzing results by the median-effect method, we have shown that there is synergistic cytotoxicity between BrdUrd and bleomycin. Synergism is evident when BrdUrd is administered prior to bleomycin or when the two drugs are applied simultaneously and is evident at a variety of BrdUrd:bleomycin concentration ratios. Alkaline elution of DNA from cells exposed to BrdUrd and bleomycin demonstrated greater single strand break formation than expected from the individual single strand break frequencies induced by each drug alone. BrdUrd did not affect the rate of repair of bleomycin-induced single strand breaks or the formation of double strand breaks. Although the mechanism of this interaction at the molecular level is unclear, our studies suggest that a direct interaction of bleomycin with BrdUrd-substituted DNA may be the cause of the synergism of these two agents.

Citations Scopus - 13
1988 Ackland SP, Schilsky RL, Beckett MN, Weichselbaum RR, 'Synergistic Cytotoxicity and DNA Strand Break Formation by Bromodeoxyuridine and Bleomycin in Human Tumor Cells', Cancer Research, 48 4256-4260 (1988)

5-Bromo-2¿-deoxyuridiiie (BrdUrd) is a thymidine analogue whose cellular effects are related to its incorporation into DNA. BrdUrd is a known radiosensitizing agent that could po... [more]

5-Bromo-2¿-deoxyuridiiie (BrdUrd) is a thymidine analogue whose cellular effects are related to its incorporation into DNA. BrdUrd is a known radiosensitizing agent that could potentially enhance the activity of chemotherapeutic agents that interact directly with DNA. Therefore we studied the interaction of BrdUrd and bleomycin in a human head and neck squamous carcinoma cell line, SQ20B. Using a colony-forming assay and analyzing results by the median-effect method, we have shown that there is synergistic cytotoxicity between BrdUrd and bleomycin. Synergism is evident when BrdUrd is administered prior to bleomycin or when the two drugs are applied simultaneously and is evident at a variety of BrdUrd:bleomycin concentration ratios. Alkaline elution of DNA from cells exposed to BrdUrd and bleomycin demonstrated greater single strand break formation than expected from the individual single strand break frequencies induced by each drug alone. BrdUrd did not affect the rate of repair of bleomycin-induced single strand breaks or the formation of double strand breaks. Although the mechanism of this interaction at the molecular level is unclear, our studies suggest that a direct interaction of bleomycin with BrdUrd-substituted DNA may be the cause of the synergism of these two agents. © 1988, American Association for Cancer Research. All rights reserved.

Citations Scopus - 1
1988 Ackland SP, Choi KE, Ratain MJ, Egorin MJ, Williams SF, Sinkule JA, Bitran JD, 'Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6 1192-1196 (1988)

Thiotepa is an established alkylating agent whose pharmacokinetics in standard doses are well defined. In order to ascertain whether dose-dependent variations in pharmacokinetics ... [more]

Thiotepa is an established alkylating agent whose pharmacokinetics in standard doses are well defined. In order to ascertain whether dose-dependent variations in pharmacokinetics occur, we have undertaken an analysis of plasma thiotepa levels in 16 patients entered on a phase I-II study of bialkylator chemotherapy. High-dose thiotepa (1.8 to 7.0 mg/kg) and cyclophosphamide (2.5 g/m2) were administered intravenously (IV) on days -6, -4, and -2 followed by autologous marrow reinfusion on day 0. Plasma and urinary thiotepa was assayed by gas chromatography. Biexponential plasma decay curves were seen in ten patients, with a t 1/2 alpha of 10.0 +/- 6.4 minutes, a t 1/2 beta of 174 +/- 61 minutes and a total body clearance of 379 +/- 153 mL/h/kg (mean +/- SD). Six patients displayed monoexponential plasma decay curves with a terminal t 1/2 of 137 +/- 83 minutes and a total body clearance of 440 +/- 195 mL/h/kg. Although there was a trend toward reduced plasma clearance in the three patients treated at the highest dose level, the available data suggest that metabolic clearance mechanisms for thiotepa were not saturated with the doses used in this study. By stepwise regression analysis, linear functions using only 15-minute and four-hour postinfusion plasma levels were derived that correlated closely with area under the plasma concentration X time curves (AUC) (P less than .002). We conclude that high-dose thiotepa results in similar pharmacokinetic values to conventional doses with no apparent dose-dependent variation. The value of specific time points to predict AUC and clearance will require prospective evaluation.

Citations Scopus - 39
1987 Ackland SP, Westbrook CA, Diaz MO, Le Beau MM, Rowley JD, 'Evidence favoring lineage fidelity in acute nonlymphocytic leukemia: Absence of immunoglobulin gene rearrangements in FAB types M4 and M5', Blood, 69 87-91 (1987)

The concept of lineage fidelity in acute leukemia has recently been challenged by the finding of rearrangements of the immunoglobulin heavy chain genes in a leukemic cell line and... [more]

The concept of lineage fidelity in acute leukemia has recently been challenged by the finding of rearrangements of the immunoglobulin heavy chain genes in a leukemic cell line and in a small number of sporadic cases of acute nonlymphocytic leukemia with a monocytic phenotype. We therefore screened leukemic blood or bone marrow samples of 33 adult patients with acute nonlymphocytic leukemia of FAB types M4 (23 patients) and M5 (10 patients); 28 were obtained at diagnosis and 5 at relapse. All cases were well characterized pathologically and histochemically. Cytogenetic analysis performed in each case demonstrated karyotypes that were representative of those generally seen in these types of leukemia, with a clonal abnormality present in all except 9 of 32 patients who were successfully studied. DNA prepared from each sample was digested with the restriction enzyme BamH1 and analyzed by Southern blot hybridization to probes for the J(H) region of the immunoglobulin heavy chain. All 33 cases had DNA retained in the germline configuration with no evidence of rearrangement. This finding supports the concept of lineage fidelity, and suggests that true interlineage infidelity, myeloid to lymphoid, is a rare occurrence in adult acute nonlymphocytic leukemia.

Citations Scopus - 13
1987 Ackland SP, Schilsky RL, 'High-dose methotrexate: A critical reappraisal', Journal of Clinical Oncology, 5 2017-2031 (1987)

High-dose methotrexate (HDMTX) with leucovorin (LV) rescue has been used as a therapeutic strategy in oncology for more than a decade. Administration of HDMTX results in tumoricid... [more]

High-dose methotrexate (HDMTX) with leucovorin (LV) rescue has been used as a therapeutic strategy in oncology for more than a decade. Administration of HDMTX results in tumoricidal plasma concentrations of the drug without significant host toxicity, provided that plasma MTX levels are monitored and LV rescue is properly administered. The original premise of LV rescue was that the provision of reduced folate to normal cells would circumvent the metabolic block produced by MTX and allow resumption of DNA synthesis, although the presumed therapeutic selectivity of leucovorin has not yet been adequately explained. Despite a strong pharmacologic rationale and a vast clinical experience, HDMTX with leucovorin rescue has not been shown to be unequivocally superior to conventional doses of MTX in any clinical situation except, perhaps, for treatment of osteogenic sarcoma and childhood acute leukemia. While HDMTX is an important component of effective treatment regimens for these diseases, its precise contribution to the success of these regimens remains undefined. Although HDMTX can theoretically overcome all known mechanisms of MTX resistance, not data exist to suggest that this can be accomplished in the clinic. Thus, this well-known but poorly understood treatment regimen must remain a subject of clinical investigation rather than a part of routine clinical practice.

Citations Scopus - 160
1987 Bishop JF, Wolf M, Matthews JP, Scott K, Ackland S, Yuen K, et al., 'Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy', Cancer Treatment Reports, 71 1007-1011 (1987)

To further define optimal combinations of antiemetics, high-dose metoclopramide and lorazepam (M+L) were compared with prochlorperazine and lorazepam (P+L) in a randomized, double... [more]

To further define optimal combinations of antiemetics, high-dose metoclopramide and lorazepam (M+L) were compared with prochlorperazine and lorazepam (P+L) in a randomized, double blind, cross-over study. Both patient and observer assessments were documented in 66 patients receiving cisplatin and noncisplatin chemotherapy. M+L significantly reduced the severity of vomiting (P = 0.01), duration of vomiting (P = 0.05), and number of vomiting episodes (P = 0.003). Comparing the severity or duration of nausea, M+L and P+L were not significantly different. M+L significantly reduced severity of vomiting (P = 0.005) and number of vomiting episodes (P = 0.03) in the cisplatin subset. The number of vomiting episodes was also reduced in the noncisplatin subset (P = 0.03). When asked to nominate a preferred regimen, 41% of patients preferred P+L, 35% preferred M+L, and 24% rated them equally. M+L was associated with significantly more anxiety and less sedation than P+L. Patient assessments produced similar results to observer assessments but gave a broader understanding of our patients' tolerance of chemotherapy. M+L is a superior regimen in controlling vomiting induced by chemotherapy.

Citations Scopus - 7
1985 Ackland SP, Bitran JD, Dowlatshahi K, 'Management of locally advanced and inflammatory carcinoma of the breast', Surgery Gynecology and Obstetrics, 161 399-408 (1985)

From the data presented, there seems little doubt that multimodality systemic and local therapy offers the best chance of long term control and survival in patients with locally a... [more]

From the data presented, there seems little doubt that multimodality systemic and local therapy offers the best chance of long term control and survival in patients with locally advanced noninflammatory and inflammatory carcinoma of the breast. However, the best method of sequencing these modalities remains inadequately defined. The rationale for systemic therapy is that systemic micrometastases are present at diagnosis; since almost all patients die from systemic disease, it would seem preferable to use chemotherapy first, while the disseminated tumor burden is low. Furthermore, this would allow an assessment of local response to the agents administered. However, chemotherapy almost never sterilizes bulky local disease, and local control rates are significantly improved by concurrent or sequential use of a local modality. From the information presented, it would appear that combined operation and radiotherapy may give a better outcome than either modality alone. However, in series in which chemotherapy plus one local modality are used, the five year, local failure rates were 20 to 35 per cent; with the use of two local modalities, the local failure rate was not significantly better (16, 20 and 22 per cent). The full effect of using two local modalities with systemic chemotherapy has not been statisfactorily explored to date. Many groups have suggested that the local control rate is proportional to the dose of radiotherapy given. Since iridium192 implantation permits larger doses of radiotherapy to the local tumor without an apparent increase in toxicity, it holds great promise as a means of improving local control in this disease and should be considered in all instances. Randomized studies comparing iridium192 with operation as an adjunct to external beam radiotherapy are needed. Although there is little doubt that combination systemic chemotherapy is mandatory for improved survival in these patients, the appropriate drugs, combination and scheduling are yet to be defined. Data from studies of metastatic carcinoma of the breast indicate that combinations of two to four drugs, including doxorubicin, give the best response rates. Recently, a number of anthracycline analogues have been studied, in particular mitoxantrone, with response rates comparable to doxorubicin but with less toxicity. These agents could be used effectively in future chemotherapy programs for locally advanced and inflammatory carcinoma of the breast. The place of endocrine manipulation also remains undefined. in general, women who present with carcinoma of the breast later in life are more likely to have hormone receptor positive, endocrine responsive tumors. Extrapolating from data obtained in studies of metastatic carcinoma of the breast, a significant chance of response to tamoxifen citrate could be expected in patients with estrogen or progesterone receptor positive tumors or in postmenopausal patients with an unknown hormone receptor status. However, in locally advanced carcinoma, conclusive data on the hormone responsiveness or the prognostic importance of hormone receptor status have not thus far been forthcoming. The rationale for concurrent chemotherapy and tamoxifen citrate is dubious, and this combination may in fact be detrimental. The apparent lack of improvement in survival beyond that obtained by current multimodality therapy is due to inherent inadequacies in our current systemic management. Chemotherapy is able to improve the short term survival and reduce local morbidity but apparently without effecting a cure. Although the optimal dose and duration remain unclear, it appears that prolonged treatment improves survival. Nevertheless, in order to optimize the chances of each patient, it is imperative that they receive planned multimodality therapy in a setting in which physicians, surgeons and radiotherapists with specific interest and experience in managing this disease can cooperate harmoniously to achieve this end. Furthermore, in ord...

Citations Scopus - 14
1985 Ackland SP, Hillcoat BL, 'Immediate hypersensitivity to mannitol: A potential cause of apparent hypersensitivity to cisplatin', Cancer Treatment Reports, 69 562-563 (1985)
Citations Scopus - 13
1984 Hallam LJ, van der Weyden MB, Ackland SP, Bagnara AS, Whiteside MG, 'The biochemical and clinical consequences of 2'-deoxycoformycin in T cell chronic lymphocytic leukaemia', Scandinavian Journal of Haematology, 32 55-64 (1984)

The mechanisms for cell toxicity with adenosine deaminase by 2'-deoxycoformycin (dCF) in non replicating lymphoid cells include S-adenosylhomocysteine (SAH) hydrolase inactivation... [more]

The mechanisms for cell toxicity with adenosine deaminase by 2'-deoxycoformycin (dCF) in non replicating lymphoid cells include S-adenosylhomocysteine (SAH) hydrolase inactivation and reduction of cellular ATP content. These postulates were explored in a patient with T-CLL receiving dCF with a resultant fall in peripheral blood lymphocytes from 740 x 109/l to 90 x 109/l over 15 d. In red cells there was complete inhibition of adenosine deaminase and AH hydrolase activities, progressive deoxyadenosine triphosphate (dATP) accumulation and ATP depletion but no significant alteration in adenosine monophosphate (AMP) deaminase activity or distribution in purine intermediates from radioactive adenosine. In T-CLL lymphocytes, there was incomplete lymphoid SAH hydrolase inactivation, reduced AMP deaminase activity and progressive dATP accumulation. The limited decrease in lymphocyte ATP content was related more to dCF administration than dATP accumulation, nor accompanied by significant changes in distribution of purine intermediates from adenosine. These findings suggest that ATP depletion with dCF therapy does not reflect AMP deaminase activity modulation nor is of critical importance for cell toxicity. The exact role for elevated cellular dATP content and SAH hydrolase inactivation in this toxicity remains to be established.

Citations Scopus - 5
1983 Ackland SP, Bishop JF, Whiteside MG, 'Acyclovir therapy in patients with malignant disease and disseminated herpes zoster', Medical Journal of Australia, 1 637-638 (1983)

Acyclovir is a new antiviral agent which is active in vitro and in vivo against a variety of herpesviruses. Two cases are reported in which intravenous administration of acyclovir... [more]

Acyclovir is a new antiviral agent which is active in vitro and in vivo against a variety of herpesviruses. Two cases are reported in which intravenous administration of acyclovir arrested the progress of disseminated herpes zoster within 24 to 48 hours after the beginning of therapy. There was no evidence of toxicity. Thus, acyclovir appears to be useful in the therapy of herpes zoster, but this requires evaluation.

Citations Scopus - 1
Show 115 more journal articles

Conference (44 outputs)

Year Citation Altmetrics Link
2015 Ackland SP, Sakoff JA, Johnson C, Garg MB, 'OPTIMAL TDM AND PHARMACODYNAMICS OF MITOTANE IN ADRENOCORTICAL CANCER (ACC) IN CHILDREN AND ADULTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Jennette Sakoff
2015 Zdenkowski N, Plowman L, Hall S, Jones D, Ackland S, 'MIDKINE (MK) AS A PREDICTIVE BIOMARKER IN METASTATIC COLORECTAL CANCER (mCRC)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Sharron Hall
2015 Fradgley E, Paul C, Bryant J, Collins N, Ackland S, Bellamy D, Levi C, 'ADVANCING COLLABORATIVE QUALITY IMPROVEMENT IN TERTIARY SETTINGS: DO CHRONIC DISEASE OUTPATIENTS AND HEALTH PROFESSIONALS IDENTIFY SIMILAR TYPES AND NUMBERS OF QUALITY INITIATIVES?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Chris Levi, Chris Paul
2015 Garg M, Galettis P, Goulooze S, Clingan P, Ranson M, Sakoff J, et al., 'THERAPEUTIC DRUG MONITORING FOR CANCER PATIENTS RECEIVING CHEMOTHERAPY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Jennette Sakoff, Jen Martin, Peter Galettis
2015 Garg M, Ackland S, McCluskey A, Scorgie F, Lincz L, McCluskey S, et al., 'THE PROTEIN PHOSPHATASE INHIBITOR CANTHARIDIN, POTENTIATES THE EFFECT OF ALL-TRANS RETINOIC ACID IN ACUTE PROMYLOCYTIC LEUKEMIA CELLS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Jennette Sakoff, Adam Mccluskey, Lisa Lincz
2014 Bryant J, Sanson-Fisher R, Fradgley L, Regan T, Hobden B, Ackland S, Turon H, 'ONCOLOGY PATIENTS OVERWHELMINGLY SUPPORT TISSUE BANKING', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Timothy Regan, Rob Sanson-Fisher
2014 Ackland SP, Garg MB, Tacon L, Johnson C, Sakoff J, 'Mitotane pharmacodynamics in adrenocortical cancer in children and adults.', JOURNAL OF CLINICAL ONCOLOGY (2014)
2014 Booth CM, Vardy JL, Gill S, Jonker DJ, O'Callaghan CJ, Friedenreich C, et al., 'A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21).', JOURNAL OF CLINICAL ONCOLOGY (2014)
2014 Baylock B, Dhillon HM, Courneya K, O'Callaghan C, O'Brien A, Goddard AM, et al., 'A PHASE III STUDY OF THE IMPACT OF A PHYSICAL ACTIVITY PROGRAM ON DISEASE-FREE SURVIVAL IN PATIENTS WITH HIGH-RISK STAGE II OR STAGE III COLON CANCER: A RANDOMIZED CONTROLLED TRIAL (NCIC CTG CO.21)', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
2014 Baylock B, Dhillon HM, Goddard EM, Turner J, Rice H, Kabourakis M, et al., 'THE COLON HEALTH AND LIFE-LONG EXERCISE CHANGE (CHALLENGE) TRIAL: PARTICIPANT ADHERENCE TO FITNESS ASSESSMENTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
2014 Ackland SP, Zdenkowski N, Adler K, Hall S, Jones D, 'MIDKINE AS A PREDICTIVE MARKER IN METASTATIC COLORECTAL CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Sharron Hall
2014 Ackland SP, Scott RJ, Moscato P, Ovchinkova L, 'A PLATFORM FOR PHARMACOGENOMIC ANALYSIS OF ADVERSE DRUG REACTIONS IN CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Rodney Scott, Pablo Moscato
2014 Agrez M, Garg MB, Parker S, Ackland SP, 'DEVELOPMENT OF INTEGRIN-DERIVED PEPTIDE-BASED ANTICANCER COMPOUNDS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
2014 Garg MB, Sakoff JA, Johnson C, Bonaventura A, Ackland SP, 'CLINICAL STUDY OF MITOTANE PHARMACODYNAMICS IN ADRENOCORTICAL CANCER IN CHILDREN AND ADULTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Jennette Sakoff
2014 Prawira A, Garg MB, Sakoff JA, Lincz LF, Adler K, Scorgie FE, Ackland SP, 'FACTORS PREDICTING RESPONSE AND SURVIVAL IN COLORECTAL CANCER PATIENTS RECEIVING ADJUVANT 5-FLUOROURACIL CHEMOTHERAPY: 10-YEAR FOLLOW-UP OF A PROSPECTIVE PATIENT COHORT', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Jennette Sakoff, Lisa Lincz
2014 Guo ST, Chi MN, Yang RH, Guo XY, Wang CY, Zan LQ, et al., 'INOSITOL POLYPHOSPHATE 4-PHOSPHATASE II PROMOTES PI3K SIGNALING AND FUNCTIONS AS AN ONCOGENIC REGULATOR IN HUMAN COLON CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Xu Zhang, Rodney Scott, Chenchen Jiang, Rick Thorne, Lei Jin
2013 Girgis A, Bonaventura T, Bonevski B, Hogan M, Boyes A, Proietto T, et al., 'FEASIBILITY STUDY OF AN ONCOLOGY NURSE PRACTITIONER MODEL OF CARE IN A RURAL CANCER SETTING', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2013) [E3]
Co-authors Allison Boyes, Billie Bonevski
2012 Upanal NN, Ackland SP, Bonaventura A, McElduff P, 'Early rise in blood pressure to predict clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with first-line bevacizumab', JOURNAL OF CLINICAL ONCOLOGY (2012) [E3]
2012 Sakoff JA, Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, 'Predicting chemotherapy-induced toxicity in cancer patients from peripheral blood telomere length', European Journal of Cancer (2012) [E3]
Co-authors Jennette Sakoff, Lisa Lincz
2012 Goddard EM, Dhillon HM, Turner J, Kabourakis M, Beale PJ, Goodwin A, et al., 'The impact of physical activity on disease-free survival in patients with high-risk stage II or III colon cancer: One month screening results', Asia-Pacific Journal of Clinical Oncology (2012) [E3]
2012 Upanal NN, Ackland S, Bonaventura A, McElduff P, 'Improved clinical outcomes in metastatic colorectal cancer patients on first-line chemotherapy with bevacizumab can be predicted by early rise in blood pressure', Asia-Pacific Journal of Clinical Oncology (2012) [E3]
2011 Price TJ, Zannino D, Wilson K, Simes J, Van Hazel GA, Robinson BA, et al., 'Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)', JOURNAL OF CLINICAL ONCOLOGY (2011)
2010 Garg M, Sakoff JA, Ackland S, 'A simple HPLC method to measure plasma mitotane and its two main metabolites in adrenocortical cancer patients', AACR 101st Annual Meeting 2010. Abstracts (2010) [E3]
Co-authors Jennette Sakoff
2010 Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Telomere length in peripheral blood mononuclear cells (PBMNC) predicts for leukopenia, neutropenia and mucositis in colorectal cancer patients treated with 5FU', AACR 101st Annual Meeting 2010. Abstracts (2010) [E3]
Co-authors Jennette Sakoff, Lisa Lincz
2010 Ackland S, 'Challenges in clinical trials design and management in the 21st century', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book (2010) [E3]
2010 Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Short telomeres in PBMNC predicts for haematological toxicity in colorectal cancer patients treated with 5FU', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book (2010) [E3]
Co-authors Jennette Sakoff, Lisa Lincz
2010 Ngan S, Fisher R, Goldstein D, Solomon M, Burmeister B, Ackland SP, et al., 'A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS)', JOURNAL OF CLINICAL ONCOLOGY (2010)
Citations Web of Science - 10
2009 Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, et al., 'GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC)', JOURNAL OF CLINICAL ONCOLOGY (2009) [E3]
Citations Web of Science - 2
2007 Sobrero A, Young S, Balcewicz M, Chiara S, Perez-Carrion R, Mainwaring P, et al., 'A large phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in metastatic CRC: AVIRI', Annals of Oncology (2007) [E3]
2007 Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, et al., 'Final data from a large phase II trial of first-line bevacizurnab plus classic or modified FOLFIRI in metastatic colorectal cancer (CRC)', European Journal of Cancer Supplements (2007) [E3]
Citations Web of Science - 1
2007 Ngan S, Fisher R, Mackay J, Solomon M, Burmeister B, Goldstein D, et al., 'Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04)', European Journal of Cancer Supplements (2007) [E3]
Citations Web of Science - 5
2007 Ackland S, Dhillon H, Jakob L, 'The COSA and Cooperative Groups Enabling Project: What is intended to be accomplished', Asia Pacific Journal of Clinical Oncology (2007) [E3]
2007 Ackland S, Dhillon H, 'Improving processes across all Cancer Cooperative Trials Groups through Standard Operating Procedures (SOPS)', Asia Pacific Journal of Clinical Oncology (2007) [E3]
2006 Stockler MR, Sourjina T, Harvey V, Frances P, Byrne M, van Hazel G, et al., 'A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment.', BREAST CANCER RESEARCH AND TREATMENT (2006)
Citations Web of Science - 7
Co-authors John Forbes
2006 Sobrero A, Ackland S, Carrion RP, Chiara S, Clarke S, Giron CG, et al., 'Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.', JOURNAL OF CLINICAL ONCOLOGY (2006)
Citations Web of Science - 5
2006 Sobrero A, Ackland S, Perez Carrion R, Chiara S, Clarke S, Garcia Giron C, et al., 'First-line bevacizumab plus infusional 5-FU/irinotecan in metastatic CRC: Initial data from the AVIRI trial', ANNALS OF ONCOLOGY (2006)
2006 Sobrero A, Ackland S, Carrion RP, Chiarra S, Clarke S, Giron CG, et al., 'Aviri, a large phase II trial of first-line bevacizumab plus infusional 5-FU/leucovorin and irinotecan (FOLFIRI) in metastatic CRC', ANNALS OF ONCOLOGY (2006)
2006 Girgis A, Boyes AW, Clinton-Mcharg T, Ackland S, Pr H, 'Proactive, routine monitoring and intervention to reduce the psychosocial impact of cancer and its treatment in outpatient oncology services', Psycho-Oncology:Journal of the psychological, social and behavioral dimension of cancer (2006) [E3]
Co-authors Tara Clinton-Mcharg, Allison Boyes
2004 Kacen L, Madjar I, Denham J, Ackland S, Aried S, 'The patient-other dynamics of the decision to forgo or stop active treatment for cancer', Palliative Medicine (2004) [E3]
Co-authors Jim Denham
2003 Smithers BM, Burmeister BH, Fitzgerald L, Gebski V, Denham J, Devitt P, et al., 'A randomized controlled trial of surgery alone compared with chemoradiation & surgery: a focus on the surgical outcomes', ANNALS OF SURGICAL ONCOLOGY (2003)
Citations Web of Science - 3
Co-authors Jim Denham
2002 Sakoff JA, Ackland SP, Garg MB, Walkom CC, McCluskey A, 'Protein phosphatase 2A, a novel and unexplored anticancer target', EUROPEAN JOURNAL OF CANCER (2002)
Co-authors Adam Mccluskey, Jennette Sakoff
2001 Keath R, Stewart J, Ackland S, Bonaventura A, 'Guidelines for the use of colony stimulating factors in patients receiving adjuvant chemotherapy for breast cancer', Proceedings in European Journal of Cancer (2001) [E3]
2000 Peters GJ, De Bruin M, Fukushima M, Van Triest B, Hoekman K, Pinedo HM, Ackland SP, 'Thymidine phosphorylase in angiogenesis and drug resistance: Homology with platelet-derived endothelial cell growth factor', Advances in Experimental Medicine and Biology (2000)
Citations Scopus - 3
1997 Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, et al., 'A randomized study of paclitaxel versus cyclophosphamide/methotrexate/- fluorouracil/prednisone in previously untreated patients with advanced breast cancer: Preliminary results', Seminars in Oncology (1997)

When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity. ... [more]

When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity. This trial was undertaken to compare paclitaxel with standard chemotherapy as front-line treatment for this disease. Patients with measurable or evaluable metastatic breast cancer, no prior chemotherapy for metastatic disease, and Eastern Cooperative Oncology Group performance status of 0 to 2 were randomized to receive either paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles over 24 weeks or standard treatment with oral cyclophosphamide 100 mg/m2/d days 1 to 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5- fluorouracil 600 mg/m2 days 1 and 8, and oral prednisone 40 mg/m2 daily days 1 to 14 (CMFP) for six cycles over 24 weeks. Patients whose disease progressed or relapsed were recommended for second-line therapy with epirubicin. Accrual has been completed with 209 patients randomized, and an interim analysis of the first 100 patients is reported here. Analysis of quality of life, assessed by the linear analogue scale and overall quality of life indices, is ongoing. Objective response occurred in 31% (confidence interval, 19% to 45%) with paclitaxel and 35% (confidence interval, 22% to 51%) with CMFP, with stable disease in an additional 33% and 29%, respectively. Median time to progression was 5.5 months with paclitaxel and 6.4 months with CMFP, with a median survival of 17.3 months for patients treated with paclitaxel and 11.3 months for those given CMFP. Grades 3 and 4 neutropenia occurred in 64% of patients with paclitaxel and 63% with CMFP. However, febrile neutropenia was the primary reason for hospitalization in 1% of paclitaxel courses, compared with 8% with CMFP. Major infections (World Health Organization grade 4) were seen in 7% of patients treated with CMFP, but in none of those given paclitaxel. Moderate or severe mucositis occurred in 13% of paclitaxel and 27% of CMFP patients. Alopecia and peripheral neuropathy were more common with paclitaxel. Quality of life assessments in the first 100 patients suggest better overall results for those treated with paclitaxel compared with CMFP. Preliminary analyses suggest that single- agent paclitaxel is well tolerated and provides control of metastatic cancer comparable to that of CMFP combination therapy when used as front-line therapy in an outpatient setting.

Citations Scopus - 2
Show 41 more conferences
Edit

Grants and Funding

Summary

Number of grants 35
Total funding $19,676,884

Click on a grant title below to expand the full details for that specific grant.


20161 grants / $21,959

Bioimpedence Scales$21,959

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Jennifer Martin, Doctor Peter Galettis, Conjoint Professor Stephen Ackland
Scheme Equipment Grant
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1600825
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20155 grants / $887,656

Advanced Technical Support for Oncology Single Cell Analysis Technologies$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor Rodney Scott, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Craig Gedye, Doctor Pradeep Tanwar, Doctor Chen Chen Jiang, Doctor Matt Dun, Professor Paul de Souza, Associate Professor Kevin Spring, Dr Tao Liu
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2015
Funding Finish 2018
GNo G1500824
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Professor Marjorie Walker, Professor Xu Dong Zhang, Doctor Pradeep Tanwar, Doctor Nikola Bowden, Doctor Craig Gedye, Doctor James Lynam, Doctor Kelly Kiejda, Doctor Jennette Sakoff, Mr Loui Rassam, Dr Tara Roberts, Professor Soon Lee, Dr Betty Kan
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2015
Funding Finish 2018
GNo G1500825
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

HNELHD Cancer Network Projects $137,718

Funding body: Hunter New England Local Health District

Funding body Hunter New England Local Health District
Project Team Conjoint Professor Stephen Ackland, Conjoint Associate Professor Anthony Proietto
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2016
GNo G1500910
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$124,938

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Stephen Ackland, Doctor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Associate Professor Christopher Scarlett, Doctor Pradeep Tanwar, Doctor Kathryn Skelding, Doctor Rick Thorne, Doctor Nikola Bowden
Scheme Research Equipment Grant
Role Lead
Funding Start 2015
Funding Finish 2016
GNo G1500598
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$25,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Doctor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Associate Professor Christopher Scarlett, Doctor Pradeep Tanwar, Doctor Kathryn Skelding, Doctor Rick Thorne, Doctor Nikola Bowden
Scheme Equipment Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1500953
Type Of Funding Internal
Category INTE
UON Y

20146 grants / $6,644,918

Hunter Cancer Research Alliance; HCRA$5,978,356

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Stephen Ackland, Professor Rodney Scott, Professor John Forbes, Laureate Professor Robert Sanson-Fisher, Professor Xu Dong Zhang, Conjoint Associate Professor Anthony Proietto, Conjoint Professor Peter Greer, Associate Professor Christine Paul
Scheme Translational Cancer Research Centre Grants
Role Lead
Funding Start 2014
Funding Finish 2019
GNo G1301098
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Sub-Project - Hunter Cancer Research Alliance; HCRA$285,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Stephen Ackland
Scheme Translational Cancer Research Centre Grants
Role Lead
Funding Start 2014
Funding Finish 2019
GNo GS140009
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

High Throughput Image Capture Platform for Translational Cancer Research$282,614

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Stephen Ackland, Professor Rodney Scott, Professor John Forbes, Professor Xu Dong Zhang, Professor Marjorie Walker, Professor Hubert Hondermarck, Doctor Craig Gedye, Doctor Rick Thorne, Mr Loui Rassam, Doctor Stephen Braye
Scheme Research Equipment Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1400626
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Biobanking Stakeholder Network Pre-Operative Consent Project$55,580

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor Rodney Scott, Conjoint Professor Stephen Ackland
Scheme Community of Practice Program
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301060
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Circulating microRNAs and RNAs as biomarkers of response and toxicity to chemoradiotherapy for oesophageal cancer$22,500

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Xu Dong Zhang, Conjoint Professor Stephen Ackland
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1401397
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

ProBBANG: Prospective study of Bevacizumab-induced Blood pressure and ANGiogenic factors as predictive biomarkers in colorectal cancer$20,868

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301365
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20132 grants / $1,559,386

HMRI MRSP Infrastructure (12-16) – CANCER $1,459,386

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland
Scheme NSW MRSP Infrastructure Grant
Role Lead
Funding Start 2013
Funding Finish 2016
GNo G1300588
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Investigation into a collaborative imaging database for NSW biobanks.$100,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor Rodney Scott, Conjoint Professor Stephen Ackland, Assoc. Prof Nicholas Hawkins, Associate Professor Deborah Marsh
Scheme Community of Practice Program
Role Investigator
Funding Start 2013
Funding Finish 2014
GNo G1300902
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20122 grants / $163,394

High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Emeritus Professor Leonie Ashman
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200555
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Mitotane pharmacodynamics in Adrenocortical Cancer in children and adults $20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff, Ms MADHU Garg
Scheme Project Grant
Role Lead
Funding Start 2012
Funding Finish 2013
GNo G1200319
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20113 grants / $2,745,074

Hunter Translational Cancer Research Unit$1,693,333

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Laureate Professor Robert Sanson-Fisher, Conjoint Associate Professor Anthony Proietto, Professor Rodney Scott
Scheme Translational Cancer Research Unit
Role Lead
Funding Start 2011
Funding Finish 2014
GNo G1100545
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Priority Research Centre for Cancer$555,811

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Professor John Forbes, Emeritus Professor Leonie Ashman, Doctor Nikola Bowden, Professor Gordon Burns, Conjoint Professor Jim Denham, Professor Hubert Hondermarck, Doctor Lisa Lincz, Doctor Jennette Sakoff, Associate Professor Peter Stanwell, Doctor Rick Thorne, Doctor Nikki Verrills
Scheme Priority Research Centre
Role Lead
Funding Start 2011
Funding Finish 2016
GNo G1101013
Type Of Funding Internal
Category INTE
UON Y

HMRI MRSP Infrastructure (11-12)-Cancer $495,930

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland
Scheme NSW MRSP Infrastructure Grant
Role Lead
Funding Start 2011
Funding Finish 2012
GNo G1101207
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20102 grants / $1,061,705

Feasibility study of an oncology nurse practitioner model of care at improving outcomes in a rural cancer setting$557,634

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Afaf Girgis, Conjoint Associate Professor Anthony Proietto, Professor Billie Bonevski, Doctor Allison Boyes, Conjoint Professor Stephen Ackland, Doctor Anthony Bonaventura, Mr Douglas Bellamy
Scheme Translational Health Service Research Grant
Role Investigator
Funding Start 2010
Funding Finish 2012
GNo G0190563
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

HMRI MRSP Infrastructure Grant (10-11) - CANCER$504,071

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Emeritus Professor Leonie Ashman, Conjoint Professor Stephen Ackland
Scheme NSW MRSP Infrastructure Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1100269
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20092 grants / $613,916

Provision of non-physical infrastructure support to enhance the breast cancer clinical trials research activities of the ANZ BCTG and its ability to build productive research collaborations$330,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor John Forbes, Associate Professor Frances Boyle, Conjoint Professor Stephen Ackland, Professor Alan Coates
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2009
Funding Finish 2012
GNo G0190219
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

MRSP Infrastructure (09-10) Cancer$283,916

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Emeritus Professor Leonie Ashman, Conjoint Professor Stephen Ackland
Scheme NSW MRSP Infrastructure Grant
Role Investigator
Funding Start 2009
Funding Finish 2010
GNo G0900172
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20082 grants / $1,191,290

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
Scheme NSW MRSP Infrastructure Grant
Role Lead
Funding Start 2008
Funding Finish 2009
GNo G0188622
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

HMRI Senior Research Fellow$160,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor John Attia, Emeritus Professor Maree Gleeson, Professor Rodney Scott, Conjoint Professor Vaughan Carr, Conjoint Professor Stephen Ackland, Professor Michael Hazelton, Professor Trevor Day
Scheme Senior Fellowship
Role Investigator
Funding Start 2008
Funding Finish 2009
GNo G0188558
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20071 grants / $12,214

(102) Hunter Medical Research Institute - Cancer$12,214

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland
Scheme Publication Performance Grant
Role Lead
Funding Start 2007
Funding Finish 2008
GNo G0187977
Type Of Funding Internal
Category INTE
UON Y

20061 grants / $621,143

20053 grants / $3,677,564

Protocol development, web-based data collection and date quality assurance for all Cancer Cooperative Trials Groups$1,840,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Stephen Ackland, Professor Alan Coates, Professor John Zalcberg, Professor Max Wolf, Dr Kwun Fong, Professor John Forbes, Dr Helen Irving, Dr Guy Toner, Professor Michael Friedlander, Professor John Thompson, Dr David Ball, Professor John Simes
Scheme Enabling Grants - Clinical Trials Resources
Role Lead
Funding Start 2005
Funding Finish 2010
GNo G0184628
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Enhancement of the ANZBCTG research program through the provision of infrastructure funding for essential management and operational personnel and other key activities $1,720,564

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor John Forbes, Professor Alan Coates, Professor John Simes, Conjoint Professor Stephen Ackland
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2005
Funding Finish 2009
GNo G0185068
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Proactive monitoring and intervention to reduce the pyschosocial impact of cancer therapy$117,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Conjoint Professor Afaf Girgis, Doctor Allison Boyes, Conjoint Professor Stephen Ackland
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2005
Funding Finish 2005
GNo G0185057
Type Of Funding Not Known
Category UNKN
UON Y

20021 grants / $10,000

New targets for chemotherapy: anti-cancer drugs that target protein phosphatases$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff
Scheme Project Grant
Role Investigator
Funding Start 2002
Funding Finish 2002
GNo G0181459
Type Of Funding Internal
Category INTE
UON Y

20012 grants / $431,665

Investigations into the biological functioning and prognostic value of novel metastatic marker for breast cancer.$420,665

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Gordon Burns, Conjoint Professor Anthony Leong, Conjoint Professor Stephen Ackland
Scheme Project Grant
Role Investigator
Funding Start 2001
Funding Finish 2003
GNo G0179658
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Using Genetics and Pharmacokinetics to Predict Toxicity of Chemotherapy.$11,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland
Scheme Project Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo G0180063
Type Of Funding Internal
Category INTE
UON Y

20001 grants / $10,000

Pre-treatment Uracil: Dihydrouacil Ratio as a Predictor of 5FU Pharmacokinetics and Myelotoxicity of Chemotherapy.$10,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Conjoint Professor Stephen Ackland
Scheme Small Grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo G0178977
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

19991 grants / $25,000

Selective Inhibitors of Protein Phosphatases as Anti-cancer agents$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Professor Adam McCluskey, Conjoint Professor Stephen Ackland
Scheme Research Grant
Role Investigator
Funding Start 1999
Funding Finish 1999
GNo G0178390
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y
Edit

Research Supervision

Number of supervisions

Completed3
Current0

Past Supervision

Year Level of Study Research Title / Program / Supervisor Type
2007 PhD The Patterns of Care for Patients with Lung Cancer in the Hunter Region, Australia (1996-2002)
PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle
Co-Supervisor
2001 Honours Predicting myelotoxicity of 5-FU chemotherapy.
Biol Sc Not Elsewhere Classifd, University of Newcastle
Co-Supervisor
2000 Honours Influence of telomere length and telomerase activity in bone marrow progenitor cells on the time required to fully regenerate the bone marrow after an autologous peripheral blood stem cell transplantation.
Biol Sc Not Elsewhere Classifd, University of Newcastle
Co-Supervisor
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 137
New Zealand 18
United States 18
United Kingdom 12
Netherlands 11
More...
Edit

News

Brain cancer studies become reality

Brain cancer studies to become a reality after show support

March 16, 2016

Brain cancer researchers in Newcastle say that a six-figure funding windfall resulting from Paul Harragon’s appearance on I’m a Celebrity Get Me Out Of Here will unlock new international research pathways and allow a number of pilot studies and clinical trials to proceed.

Hunter scores new cancer equipment grants

August 20, 2015

NSW Health Minister Jillian Skinner has announced 17 recipients for the 2015 Cancer Institute NSW Research Equipment Grants, with University of Newcastle researchers Professor Stephen Ackland and Professor Xu Dong Zhang among them.

Cancer Boost

Major cancer boost

June 3, 2014

The Hunter Cancer Research Alliance (HCRA) has become the first regionally based organisation to receive full Translational Cancer Research Centre status and an accompanying $6.5-million funding injection from the Cancer Institute NSW.

Cancer Genome Atlas

Cancer Genome Atlas

July 17, 2013

Scientists and clinicians aim to foster targeted approach to cancer treatment by improving communication channels.

 

Conjoint Professor Stephen Ackland

Position

Director, Hunter Cancer Research Alliance
Medical Oncology
Office of the PVC Health and Medicine
Faculty of Health and Medicine

Focus area

Pharmacy and Experimental Pharmacology

Contact Details

Email stephen.ackland@newcastle.edu.au
Phone (02) 4014 3570
Mobile 0408 492868
Fax (02) 4968 0384
Link Research Networks

Office

Room NM.2
Building Mater Hospital Level 3 - New Med 2
Location Other

,
Edit